Arteris, Inc. (NASDAQ:AIP – Get Free Report) CEO K Charles Janac sold 7,147 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $10.92, for a total value of $78,045.24. Following the transaction, the chief executive officer directly owned 179,335 shares in the company, valued at approximately $1,958,338.20. This trade represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
K Charles Janac also recently made the following trade(s):
- On Friday, October 3rd, K Charles Janac sold 11,821 shares of Arteris stock. The shares were sold at an average price of $11.07, for a total value of $130,858.47.
- On Thursday, September 4th, K Charles Janac sold 2,057 shares of Arteris stock. The shares were sold at an average price of $8.73, for a total value of $17,957.61.
- On Tuesday, September 2nd, K Charles Janac sold 1,246 shares of Arteris stock. The stock was sold at an average price of $8.94, for a total value of $11,139.24.
- On Tuesday, August 5th, K Charles Janac sold 50,000 shares of Arteris stock. The shares were sold at an average price of $13.12, for a total transaction of $656,000.00.
- On Tuesday, August 5th, K Charles Janac sold 94,245 shares of Arteris stock. The shares were sold at an average price of $13.49, for a total transaction of $1,271,365.05.
Arteris Trading Up 23.7%
AIP opened at $13.58 on Tuesday. Arteris, Inc. has a 1-year low of $5.46 and a 1-year high of $14.58. The company has a market cap of $579.19 million, a price-to-earnings ratio of -16.56 and a beta of 1.45. The company’s fifty day moving average price is $9.74 and its two-hundred day moving average price is $8.47.
Wall Street Analyst Weigh In
Several analysts have recently commented on the company. TD Cowen increased their price objective on Arteris from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Arteris in a research note on Saturday, September 27th. Finally, Wall Street Zen raised shares of Arteris from a “sell” rating to a “hold” rating in a report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.00.
Read Our Latest Stock Analysis on Arteris
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Arteris during the 1st quarter valued at $95,000. Acadian Asset Management LLC grew its position in Arteris by 40.6% during the first quarter. Acadian Asset Management LLC now owns 900,723 shares of the company’s stock valued at $6,222,000 after buying an additional 260,277 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in Arteris by 48.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 249,517 shares of the company’s stock worth $1,724,000 after buying an additional 81,516 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Arteris during the fourth quarter worth about $160,000. Finally, Nuveen LLC bought a new stake in Arteris in the first quarter worth about $349,000. Hedge funds and other institutional investors own 64.36% of the company’s stock.
Arteris Company Profile
Arteris, Inc provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP.
Recommended Stories
- Five stocks we like better than Arteris
- What Does Downgrade Mean in Investing?
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Exceptional Stocks to Build Long-Term Wealth
- How to Find Undervalued Stocks
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.